Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients (PORTREAT)

Sanofi

Status: Terminated

Conditions: Prostatic Neoplasms

Study type: Observational

Funder types: Industry

Identifiers

NCT01076751

DIREG_C_05073

Details and patient eligibility

About

Primary Objective:

• Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression

Secondary Objective:

• Describe treatment patterns
• Describe the characteristics and outcomes of patients who received second-line taxane-based treatment compared to others
• Describe economic and patient-reported outcomes

Enrollment: 82 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with CRPC progressing during the course of first line docetaxel-based chemotherapy or after at least 3 cycles (equivalent to 225mg/m2) of first line docetaxel-based chemotherapy
• Patient who have given their written consent

Exclusion criteria

• Current participation in a clinical trial for the second-line treatment of prostate cancer
• Patients having received less than 3 cycles of first line docetaxel-based chemotherapy and discontinued for a reason other than disease progression or toxicity
• Patients having already started a second line treatment

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Trial design

82 participants in 1 patient group

CRPC patients